ZEUS
2026
ZEUS: Effects of Ziltivekimab Versus Placebo on Cardiovascular Outcomes in Participants With Established Atherosclerotic Cardiovascular Disease, Chronic Kidney Disease and Systemic Inflammation
In patients with atherosclerotic cardiovascular disease, chronic kidney disease and inflammation, ziltivekimab did not reduce major adverse cardiovascular events compared with placebo.
Risultato
Endpoint primario: Time to first major adverse cardiovascular event (cardiovascular death, non-fatal myocardial infarction, non-fatal stroke)
Major adverse cardiovascular events occurred in 561 participants assigned to ziltivekimab vs 565 assigned to placebo, a difference that was not statistically significant. Deaths: 538 vs 542. Compared with placebo, ziltivekimab lowered hs-CRP by 64% and IL-6 by 76%. Overall adverse event rates were similar, but serious infections were more common with ziltivekimab (20% vs 18%). Median treatment duration was 29.1 months.
- Sottotema
- IL-6 inhibition
- Disegno
- Phase 3, double-blind, placebo-controlled, event-driven trial (Novo Nordisk; about 1,070 sites); monthly subcutaneous ziltivekimab versus placebo for up to 4 years
- Arruolati
- 6376 pazienti
- Fonte
- Ridker PM. Presented at AHA Scientific Sessions 2026, 7 November. American Heart Association newsroom, Abstract 27922. Simultaneously published in N Engl J Med (doi 10.1056/NEJMoa2612126).doi 10.1056/nejmoa2612126
Discussione e critica
This large double-blind, placebo-controlled trial shows that IL-6 inhibition with ziltivekimab strongly suppressed hs-CRP and IL-6 but did not reduce hard cardiovascular events in people with atherosclerotic disease, chronic kidney disease and inflammation. The newsroom release gives event counts but no hazard ratio, confidence interval, P value or event percentages, so the precision of the neutral result cannot be judged from this source. The population had advanced atherosclerotic and kidney disease at very high risk, and median treatment of 29.1 months may have been too late in the course of disease for the drug to help. More serious infections with ziltivekimab show that the inflammatory suppression came at a safety cost and brought no outcome benefit.